AUS
NZ
UK
CA
USA
IND
Healthcare
Is ASX All Ordinaries Powering Healthcare Innovation?
April 23, 2026 12:04 PM AEST| By SamHealthcare technology trends within the ASX All Ordinaries highlight digital innovation, global expansion, and evolving market dynamics shaping Australia’s healthcare sector.
Leading ASX 100 Healthcare Stocks to Watch
April 23, 2026 10:26 AM AEST| By SamHealthcare companies including Cochlear, CSL, and ResMed highlight sector activity within the ASX 100 and All Ordinaries, reflecting evolving trends in global medical technology and equity markets.
ASX Biotech Rollercoaster: Why Telix Shares Keep Swinging
April 23, 2026 10:23 AM AEST| By SamTelix shares swing due to strong growth drivers, regulatory uncertainty, and shifting market sentiment, highlighting the balance between opportunity and volatility in the biotech sector.
ASX Healthcare Watch: Little Green Pharma Shares in Focus After Scheme Update
April 22, 2026 06:37 PM AEST| By SamLittle Green Pharma releases a scheme update, signalling ongoing corporate restructuring while highlighting transparency and strategic developments within the evolving healthcare sector.
ASX 200 Entry: Does 4DMedical’s Upgrade Change the Story?
April 22, 2026 05:55 PM AEST| By Sam4DMedical’s ASX 200 inclusion boosts visibility and liquidity, but funding needs and commercial adoption of its lung imaging technology remain key factors shaping its evolving risk and growth narrative.
Is CSL (ASX:CSL) driving ASX 200 healthcare weakness?
April 22, 2026 05:40 PM AEST| By SamHealthcare sector movements and global developments influence ASX market sentiment, with large-cap stocks like CSL shaping broader index dynamics.
ASX 200 Shocker: Cochlear Crash Deepens After Earnings Blow
April 22, 2026 05:36 PM AEST| By SamCochlear shares plunge after a sharp earnings downgrade driven by global headwinds, policy pressures, and weaker demand, highlighting short-term challenges despite ongoing innovation and long-term healthcare demand.
ASX 200 Biotech Under Pressure: Can CSL Stage a Comeback?
April 22, 2026 05:31 PM AEST| By SamCSL faces pressure amid earnings challenges and market rotation, though strong plasma therapy demand and global positioning continue to support its long-term outlook within the healthcare sector.
Why CSL Is Back in Focus Across ASX 100
April 22, 2026 05:24 PM AEST| By SamCSL remains central to Australia’s healthcare sector, with its role in biotechnology and global medical supply shaping its position within major equity indices.
ASX 200 Healthcare Giant Plunges: What’s Behind Cochlear’s Shock Fall?
April 22, 2026 05:18 PM AEST| By SamCochlear shares drop after earnings downgrade driven by weaker demand, hospital constraints, and lower referrals, highlighting near-term pressure despite ongoing innovation and long-term healthcare market opportunities.
4DMedical All Ords Entry Gains Market Focus
April 22, 2026 05:05 PM AEST| By Sam4DMedical’s inclusion in the All Ordinaries highlights healthcare technology’s expanding role in Australian equities, reflecting innovation-led sector participation and evolving market composition.
ASX 200 Healthcare Stock Under Pressure: Cochlear Faces Sharp Earnings Reset
April 22, 2026 02:07 PM AEST| By SamCochlear Ltd (ASX: COH) has reset its earnings outlook following multiple headwinds, highlighting near-term challenges within the ASX healthcare stocks sector.
ASX Healthcare Stock Expands Capital Base with Massive Share Issuance
April 22, 2026 10:24 AM AEST| By SamPercheron Therapeutics’ large share issuance highlights a major capital restructuring move, with potential impacts on liquidity, ownership dynamics, and future growth strategy.
ASX 200 Healthcare Stocks Lag: Quiet Setup for Next Rally?
April 22, 2026 10:16 AM AEST| By SamASX 200 healthcare stocks lag behind tech recovery, but strong fundamentals and long-term demand highlight potential for future sector revival.
Why Is Recce Pharma’s Indonesia Milestone Gaining Attention?
April 21, 2026 06:51 PM AEST| By SamRecce Pharmaceuticals advances its clinical journey after a successful Indonesia inspection, reinforcing trial integrity and supporting expansion across Southeast Asia’s growing healthcare market.
What Lies Ahead for Starpharma After FDA Clears DEP HER2 Path?
April 21, 2026 05:22 PM AEST| By SamStarpharma progresses DEP HER2 into clinical development following FDA guidance, highlighting innovation in targeted cancer therapies and shaping its next growth phase in oncology research.
ASX 200 Welcomes New Healthcare Player as 4DMedical Joins the Index
April 21, 2026 04:13 PM AEST| By Sam4DMedical’s inclusion in the ASX 200 marks a key milestone, boosting visibility and reinforcing its position in the growing healthcare technology sector.
Why CSL Shares (ASX: CSL) Are Facing Volatility on the S&P/ASX 200
April 21, 2026 03:33 PM AEST| By SamCSL shares (ASX: CSL) have faced volatility due to growth revisions and sector trends, though long-term fundamentals remain supported by strong global healthcare demand.
Is Telix Pharma (ASX:TLX) in ASX 200 Market Focus?
April 21, 2026 12:45 PM AEST| By SamTelix Pharmaceuticals reflects valuation-focused attention within the ASX healthcare sector, highlighting biotechnology participation and trends across ASX 100 and ASX 200 indices.
ASX 100 Pharma Stock Sees Surge in Market Focus
April 21, 2026 12:40 PM AEST| By SamTelix Pharmaceuticals reflects positioning within ASX healthcare sector, highlighting biotechnology participation and trends across ASX 100 and ASX 200 indices.
Advertise your brand on Kalkine Media